USP <1787> and <1788>

USP chapters <1787> and <1788> provide critical context for measuring and interpreting subvisible particulate matter in parenterals. While USP <788> sets the enforceable numeric limits, <1788> explains in detail how to properly execute the compendial test methods, and <1787> provides a modern, risk-based toolkit to address the unique challenges of therapeutic proteins, where aggregates themselves are a key quality and safety concern.

Key Principles & Scope

• USP <1788>: Companion to <788>; technical “how-to” for official QC methods.
• USP <1787>: Development-focused; guidance on orthogonal methods to characterize proteinaceous and process-related particles.

Cross-links: Complements USP <787> (proteins—subvisible particles) and <789> (ophthalmics).

USP <1788>: Standard Method Execution

• Light Obscuration (LO): Preferred automated method for clear, low-viscosity solutions.
• Microscopic Particle Count (MPC): Alternative when LO is unsuitable (colored, viscous, foaming).

Guidance includes instrument qualification, calibration, sample handling, and data interpretation.

USP <1787>: Expanded Toolkit for Proteins

Protein particles often evade LO/MPC detection due to low refractive index contrast, leading to undercounting.

Solution: Risk-based use of complementary methods to fully characterize particle profile.

Particle sizing/counting methods:

• Flow Imaging Microscopy (FIM): Provides both quantitative counts and morphology (distinguishes protein aggregates vs. silicone oil).
• LO/MPC: Still useful but limited for proteinaceous particles.

Supportive characterization methods:

• SEC: Quantifies soluble aggregates below subvisible range.
• DLS: Estimates hydrodynamic diameter of small aggregates.
• AUC: High-resolution distribution of aggregate sizes.

Lifecycle & Regulatory Context

QC Lot Release: USP <788> limits are enforced.

Development & Comparability: <1787>/<1788> support mechanistic understanding and risk assessment of aggregation.

Regulatory Filings: Data from these chapters provide scientific justification in BLA/MAA submissions, especially for therapeutic proteins and biosimilars.